A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN (IMVAMUNE) Smallpox Vaccine in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis

Project: Research project

StatusFinished
Effective start/end date3/1/082/28/10

Funding

  • Bavarian Nordic A/S (POX-MVA-008 // HHSN266200400072C)
  • National Institute of Allergy and Infectious Diseases (POX-MVA-008 // HHSN266200400072C)